ARTICLE | Clinical News
Bevasiranib: Phase III started
July 16, 2007 7:00 AM UTC
OPK (formerly Acuity Pharmaceuticals Inc.) began the international Phase III COBALT trial in 330 patients to compare bevasiranib dosed every 8 and 12 weeks vs. Lucentis dosed every 4 weeks. Genente...